Researchers from McMaster University and Espervita Therapeutics Inc. have identified the enzyme ATP citrate lyase (ACLY) as a key metabolic regulator of tumor-immune interactions in hepatocellular carcinoma (HCC) driven by metabolic dysfunction-associated steatohepatitis (MASH).